T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs

J A Smith; J A Bluestone

doi:10.1016/s0952-7915(97)80044-1

T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs

Curr Opin Immunol. 1997 Oct;9(5):648-54. doi: 10.1016/s0952-7915(97)80044-1.

Authors

J A Smith¹, J A Bluestone

Affiliation

¹ Ben May Institute for Cancer Research, Department of Pathology, University of Chicago, IL 60637, USA.

PMID: 9368773
DOI: 10.1016/s0952-7915(97)80044-1

Abstract

Fc receptor nonbinding anti-CD3 monoclonal antibodies show promise for clinical application, in that they suppress graft rejection without the toxicity associated with conventional anti-CD3 antibody therapy. Recent studies suggest that the mechanism of soluble anti-CD3 antibody mediated immunosuppression involves partial signaling, induced cytokine deviation and Th1 cell inactivation.

Publication types

Review

MeSH terms

Antibodies, Monoclonal
CD3 Complex / immunology*
Cytokines / immunology*
Humans
Lymphocyte Activation*
Receptors, Fc / immunology*
T-Lymphocytes / immunology*

Substances

Antibodies, Monoclonal
CD3 Complex
Cytokines
Receptors, Fc